2) 四環藥業(460 HK) 3篇有關其專利創新藥「加格列淨」臨床試驗的文獻摘要獲選在美國糖尿病協會第79屆科學年會壁報報告上刊登,且亦會在該會網上期刊Diabetes發表。該三篇摘要根據「加格列淨」的臨床試驗進度披露了部分試驗結果。「加格列淨」是一種口服鈉-葡萄糖共轉運蛋白2(「SGLT -2」)抑制劑,而SGLT -2抑制劑是治療2型糖尿病的新型口服降糖藥物,抑制腎臟對葡萄糖的重吸收,使多餘的葡萄糖經尿液排出,從而降低血糖濃度。集團指「加格列淨」在內地、美國、歐洲、日本及南韓已獲得專利權,而該藥的三期臨床研究仍在進行。
3) 中國銀河(6881 HK)按中國會計準則編製,5月淨利潤3.67億元(人民幣‧下同),按年增長45.07%;營業收入9.25億元,按年升24.11%。期內,銀河金匯淨利潤188.76萬元,按年下跌66.6%。
#FISDC {
font-size: 12px;
color:#a9a9a9;
letter-spacing: 2px;
word-spacing: 2px;
font-weight: bold;
text-decoration: none;
font-style: normal;
font-variant: normal;
text-transform: none;
}
#FISDD {
font-size: 16px;
color:#343434;
letter-spacing: 2px;
word-spacing: 2px;
font-weight: bold;
text-decoration: none;
font-style: normal;
font-variant: normal;
text-transform: none;
}
#link_bar a { padding:6px 16px; font-size:16px;font-weight:bold; text-align: center; float:centre; vertical-align:middle; display:inline-block; width: 200px;}
#link_bar a:link { color:#ffffff; background-color:#DB000C; }
#link_bar a:visited { color:#ffffff; background-color:#DB000C;}
#link_bar a:hover { color:#ffffff; background-color:#000000; }
#link_bar a:active { color:#ffffff; background-color:#DB000C; }
#tel a { font-size:16px;font-weight:bold; text-align: center; float:centre; vertical-align:middle; }
#tel a:link { color:#3399CC;}
#tel a:visited { color:#3399CC;}
#tel a:hover { color:#3399CC; }
#tel a:active { color:#3399CC; }
.glowingbutton {
background-color: #004A7F;
-webkit-border-radius: 10px;
border-radius: 10px;
border: none;
color: #FFFFFF;
cursor: pointer;
display: inline-block;
font-family: Arial;
font-size: 16px;
padding: 5px 10px;
text-align: center;
text-decoration: none;
-webkit-animation: glowing 2000ms infinite;
-moz-animation: glowing 2000ms infinite;
-o-animation: glowing 2000ms infinite;
animation: glowing 2000ms infinite;
}
@-webkit-keyframes glowing {
0% { background-color: #AF0618; -webkit-box-shadow: 0 0 1px #AF0618; color: #FFFFFF; }
50% { background-color: #DB000C; -webkit-box-shadow: 0 0 1px #DB000C; color: #FFFFFF;}
100% { background-color: #AF0618; -webkit-box-shadow: 0 0 1px #AF0618; color: #FFFFFF;}
}
@-moz-keyframes glowing {
0% { background-color: #AF0618; -moz-box-shadow: 0 0 1px #AF0618; color: #FFFFFF;}
50% { background-color: #DB000C; -moz-box-shadow: 0 0 1px #DB000C; color: #FFFFFF;}
100% { background-color: #AF0618; -moz-box-shadow: 0 0 1px #AF0618; color: #FFFFFF;}
}
@-o-keyframes glowing {
0% { background-color: #AF0618; box-shadow: 0 0 1px #AF0618; color: #FFFFFF;}
50% { background-color: #DB000C; box-shadow: 0 0 1px #DB000C; color: #FFFFFF;}
100% { background-color: #AF0618; box-shadow: 0 0 1px #AF0618; color: #FFFFFF;}
}
@keyframes glowing {
0% { background-color: #AF0618; box-shadow: 0 0 1px #AF0618; color: #FFFFFF;}
50% { background-color: #DB000C; box-shadow: 0 0 1px #DB000C; color: #FFFFFF;}
100% { background-color: #AF0618; box-shadow: 0 0 1px #AF0618; color: #FFFFFF;}
}